Quick Answer
Candel Therapeutics, Inc. reported Operating Income of -$48.27 million for fiscal year 2025.
Candel Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$48.27M | -44.6% |
| 2024 | -$33.37M | +13.1% |
| 2023 | -$38.39M | -10.6% |
| 2022 | -$34.72M | -35.0% |
| 2021 | -$25.73M | -86.3% |
| 2020 | -$13.81M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$13.21M | -50.8% | -18.2% |
| June 30, 2025 | -$11.18M | -30.4% | -37.5% |
| March 31, 2025 | -$8.13M | -2.9% | +7.2% |
| September 30, 2024 | -$8.76M | +1.2% | -2.2% |
| June 30, 2024 | -$8.57M | +10.5% | -8.5% |
| March 31, 2024 | -$7.90M | +18.0% | +10.8% |
| September 30, 2023 | -$8.86M | +0.2% | +7.5% |
| June 30, 2023 | -$9.58M | -9.4% | +0.6% |
- Candel Therapeutics, Inc. showed a decrease of -44.6% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Candel Therapeutics, Inc.’s operating income has declined by 249.5% (from -$13.81 million to -$48.27 million).
- The most recent figure is from Candel Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: